Stock HOOK HOOKIPA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
0.819 USD +1.11% Intraday chart for HOOKIPA Pharma Inc. +3.15% +1.11%
Jun. 05 HC Wainwright Adjusts Price Target on HOOKIPA Pharma to $6 From $5, Maintains Buy Rating MT
Jun. 04 Transcript : HOOKIPA Pharma Inc. - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Price Target on HOOKIPA Pharma to $6 From $5, Maintains Buy Rating
MT
Transcript : HOOKIPA Pharma Inc. - Special Call
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
GL
HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
CI
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
GL
HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting
CI
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
GL
HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
Transcript : HOOKIPA Pharma Inc. - Special Call
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
GL
HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
CI
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
GL
HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
CI
HOOKIPA Pharma Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GL
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
GL
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200
CI
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
AQ
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HOOK Stock
  4. News HOOKIPA Pharma Inc.